Research

Stay ahead in the investement world with the latest stock insights from our internal research team.

February 12, 2026

Kratos Defense & Security Solutions (KTOS) Deep Research Report: Hypersonics Hype vs. Valuation Risk in 2026

KTOS rides hypersonics momentum, but rich valuation, thin margins, and heavy capex leave little room for error. See what must go right by 2026.

DeepValue Research TeamRead article →

February 12, 2026

Agios Pharmaceuticals (AGIO) Deep Research Report: Underpriced Optionality or Value Trap in Rare Disease Biotech?

Deep dive on Agios Pharmaceuticals’ 2026 setup: AQVESME launch under REMS, mitapivat platform value, cash burn, and what investors should watch next.

DeepValue Research TeamRead article →

February 12, 2026

Under Armour (UA) Deep Research Report: Margin Squeeze, Turnaround Hopes, and Insider Buying in 2026

Under Armour’s reset is past the worst, but tariffs, promotions, and restructuring still squeeze margins. Here’s what 2026 investors should watch.

DeepValue Research TeamRead article →

February 11, 2026

SiteOne Landscape Supply (SITE) Deep Research Report: Margin Expansion Hopes vs. Volume Anxiety in 2026

SiteOne’s premium valuation hangs on 2026 margin gains despite flat demand. We break down pricing, SG&A leverage, M&A risk, and what investors should watch.

DeepValue Research TeamRead article →

February 11, 2026

Danaos Corporation (DAC) Deep Research Report: Deep Value, Dividends, And A Risky 2027–2028 Reset

Danaos (DAC) screens cheap with strong cash, dividends, and backlog. We break down upside, downside, and what 2027–2028 re-charters mean for returns.

DeepValue Research TeamRead article →

February 11, 2026

ZIM Integrated Shipping Services (ZIM) Deep Research Report: Strategic Review Optionality vs. Freight Cycle Risk in 2026

ZIM stock screens cheap, but 2026 freight pressure and sticky charter costs complicate the upside. See how the strategic review shapes risk-reward now.

DeepValue Research TeamRead article →

February 10, 2026

Cabaletta Bio (CABA) Deep Research Report: High-Risk CAR-T Breakthrough or Dilution Trap Heading Into 2027?

Deep dive on Cabaletta Bio’s CAR-T pipeline, 1H26 catalysts, financing risk, and what needs to go right before this autoimmune bet looks buyable.

DeepValue Research TeamRead article →

February 10, 2026

Strata Critical Medical (SRTA) Deep Research Report: High-Risk Healthcare Roll-Up or Underpriced Cash Machine by 2027?

Strata Critical Medical’s pivot to transplant logistics creates big upside—but tight cash and execution risk. We break down the 2026 scorecard for investors.

DeepValue Research TeamRead article →

February 10, 2026

Vertical Aerospace Ltd. (EVTL) Deep Research Report: Funding Risk vs. Flight-Test Progress in 2026

A deep dive into EVTL’s 2026 setup: piloted transition milestones, looming cash covenant risk, and what current pricing implies for forward returns.

DeepValue Research TeamRead article →

February 9, 2026

Archer Aviation (ACHR) Deep Research Report: High-Risk Air Taxi Bet or Patient Wait-for-Proof Play in 2026?

ACHR is a pre-revenue eVTOL pure play with big upside—but real dilution and execution risk. We break down milestones, valuation bands, and what to watch.

DeepValue Research TeamRead article →

February 9, 2026

AeroVironment (AVAV) Deep Research Report: High-Expectation Defense Play or Premature Entry?

Deep dive on AVAV after the BlueHalo deal: record bookings, pressured margins, cash burn, and what must improve before the stock looks buyable.

DeepValue Research TeamRead article →

February 9, 2026

Janus International Group (JBI) Deep Research Report: Waiting Out the Self‑Storage Cycle or Buying the Reset?

Our deep-dive on Janus International weighs self-storage cyclicality, credit risk, and 2026 EBITDA guidance to see if JBI stock deserves a spot on your watchlist.

DeepValue Research TeamRead article →

February 8, 2026

Carter's, Inc. (CRI) Deep Research Report: Tariffs, Amazon Risk, and 2026 Reset Milestones Investors Can’t Ignore

Carter’s faces tariff shocks, Amazon wholesale risk, and a big cost reset. Here’s what 2026 guidance and cash flow will mean for CRI shareholders.

DeepValue Research TeamRead article →

February 8, 2026

Zumiez (ZUMZ) Deep Research Report: Overvalued vs. Opportunity? What 2026 Investors Need to See First

Zumiez’s stock bakes in a clean margin story, but rising inventory and weak international trends add risk. Here’s what must improve before we’d buy.

DeepValue Research TeamRead article →

February 8, 2026

Academy Sports & Outdoors (ASO) Deep Research Report: Traffic Test vs. Margin Strength – What 2026 Investors Need to See

ASO trades at a low multiple, but traffic is weak and margins lean on temporary tailwinds. See what must improve in 2026 before calling it a clear buy.

DeepValue Research TeamRead article →

February 6, 2026

Ulta Beauty, Inc. (ULTA) Deep Research Report: Wait for Proof on Margins, Cash Flow, and Post-Target Execution

Ulta Beauty’s stock bakes in strong demand and high margins. We break down why our team is waiting for cleaner SG&A, inventory, and cash-flow signals.

DeepValue Research TeamRead article →

February 6, 2026

Fulgent Genetics (FLGT) Deep Research Report: Cash-Rich Diagnostics Turnaround or Future Biotech Cash Burn?

Deep dive on Fulgent Genetics’ cash-heavy balance sheet, diagnostics growth, and therapeutics risk to see if the current stock price undervalues the core business.

DeepValue Research TeamRead article →

February 6, 2026

Sportradar (SRAD) Deep Research Report: Can Rights Risk, Litigation, and AI Upside Coexist for 2026 Investors?

Deep dive on Sportradar’s stock: IMG ARENA integration, rights risk, PANDA antitrust overhang, AI-driven products, and what 2026 investors should watch.

DeepValue Research TeamRead article →

February 5, 2026

Evolus, Inc. (EOLS) Deep Research Report: Profitability Inflection or Value Trap in 2026?

Evolus aims for sustainable profitability in 2026. We break down the fillers ramp, Jeuveau share, risks, and what investors should watch next.

DeepValue Research TeamRead article →

February 5, 2026

Ligand Pharmaceuticals (LGND) Deep Research Report: Pricing In Perfection on 2026 Royalties – Or Patience Rewarded?

Our deep-dive on Ligand Pharmaceuticals weighs 2026 royalty guidance, FILSPARI and Ohtuvayre risk, and whether LGND stock is worth waiting for.

DeepValue Research TeamRead article →

February 5, 2026

Hims & Hers Health (HIMS) Deep Research Report: Weighing Growth Hopes Against Regulatory Risks in 2026

Hims & Hers is pivoting from GLP-1 hype to a broader health platform. We break down valuation, key 2026 catalysts, and what investors should watch.

DeepValue Research TeamRead article →

February 4, 2026

Editas Medicine (EDIT) Deep Research Report: High-Risk Pivot or Asymmetric Setup for 2026–2027 Investors?

Deep dive on Editas Medicine’s in vivo CRISPR pivot, EDIT‑401 LDL program, cash runway to 2027, and what needs to go right for upside.

DeepValue Research TeamRead article →

February 4, 2026

Anavex Life Sciences (AVXL) Deep Research Report: High-Risk Biotech or Just Overhyped Optionality in 2026?

Anavex Life Sciences trades at a rich premium to cash despite regulatory setbacks. We break down Alzheimer’s, Rett, dilution risk, and key 2026–27 catalysts.

DeepValue Research TeamRead article →

February 4, 2026

Organon & Co. (OGN) Deep Research Report: Distressed Pharma Value Play or Governance Trap in 2026?

Organon stock trades at distressed multiples after a governance scandal. We break down leverage, biosimilar growth, risks, and what must go right by 2026.

DeepValue Research TeamRead article →

February 3, 2026

IMAX Corporation (IMAX) Deep Research Report: Priced for Perfection in 2026 – Or Is It Time to Trim?

IMAX stock bakes in record box office, high margins, and perfect slate execution. We break down the real risk‑reward for investors heading into 2026.

DeepValue Research TeamRead article →

February 3, 2026

Photronics (PLAB) Deep Research Report: Overheated AI Hopes or Justified Premium at These Levels?

Photronics has surged on AI optimism, but flat revenue and heavy capex raise risk. We break down valuation, scenarios, and key catalysts for PLAB investors.

DeepValue Research TeamRead article →

February 3, 2026

Roblox (RBLX) Deep Research Report: High-Growth Platform Meets Margin Reality in 2026

Roblox is growing fast and minting cash, but rising creator and safety costs squeeze margins. We break down whether waiting on RBLX makes sense now.

DeepValue Research TeamRead article →

February 2, 2026

Angi Inc. (ANGI) Deep Research Report: Turnaround Story or Value Trap for 2026 Investors?

Deep dive on Angi’s AI-driven turnaround, shrinking revenue base, debt overhang, and what must go right by 2026 before value investors step in.

DeepValue Research TeamRead article →

February 2, 2026

Duolingo (DUOL) Deep Research Report: High-Growth Potential vs. Thin Safety Margin Going Into 2027

Duolingo stock combines elite growth and margins with a rich valuation and AI risk. We break down whether the risk/reward justifies a position now.

DeepValue Research TeamRead article →

February 2, 2026

Applied Digital (APLD) Deep Research Report: High-Beta AI Infrastructure Play With More Risk Than Margin of Safety?

Applied Digital has huge AI data center leases and a soaring share price—but heavy debt, thin margins, and concentrated customers leave little cushion.

DeepValue Research TeamRead article →

February 1, 2026

Xperi Inc. (XPER) Deep Research Report: Deep Value, Platform Risk, and What 2026 Investors Need to See

Xperi trades at low EV/EBITDA with real platform upside—but shrinking revenue. We break down valuation, risks, and key 2026 catalysts for investors.

DeepValue Research TeamRead article →

February 1, 2026

QuantumScape (QS) Deep Research Report: Overvalued Optionality or Early-Mover Edge in Solid-State EV Batteries?

Deep dive on QuantumScape’s solid‑state EV battery bet, valuation, risks, VW partnership, and what needs to go right before 2027 for shareholders.

DeepValue Research TeamRead article →

February 1, 2026

Ziff Davis (ZD) Deep Research Report: Undervalued Cash Generator or Just Another Stalled Media Roll‑Up?

Deep dive on Ziff Davis stock: valuation, cash flow, segment trends, M&A strategy, and key 2026 catalysts investors should watch before buying.

DeepValue Research TeamRead article →

January 31, 2026

TechTarget, Inc. (Informa TechTarget) (TTGT) Deep Research Report: Turnaround Potential or Value Trap After a 70% Drawdown?

Deep dive on TechTarget after a 70% drop: synergies, impairments, balance sheet risk, and what must go right for upside over the next 6–18 months.

DeepValue Research TeamRead article →

January 31, 2026

BlackLine (BL) Deep Research Report: Balanced Upside Or Value Trap for 2026 Buyers?

BlackLine’s growth has slowed, but cash flow and AI bets look interesting. We break down valuation, risks, and catalysts for BL stock in 2026.

DeepValue Research TeamRead article →

January 31, 2026

nCino (NCNO) Deep Research Report: Wait for Clarity on AI Growth, Margins, and Leverage Before Jumping In

Deep dive on nCino’s growth, AI roadmap, and balance sheet. Why we rate NCNO a “wait” and what FY27 guidance must prove before it’s a buy.

DeepValue Research TeamRead article →

January 29, 2026

Vaxcyte (PCVX) Deep Research Report: High-Risk Vaccine Upside or Better Left on the Watchlist in 2026?

Deep dive on Vaxcyte’s PCVX stock: Phase 3 risks, ACIP politics, dilution, and what needs to go right before 2027 for upside to materialize.

DeepValue Research TeamRead article →

January 29, 2026

Krystal Biotech (KRYS) Deep Research Report: Is Growth Priced In Already – Or Is There Still Upside for 2026 Investors?

KRYS has become a top gene therapy winner, but at ~40x earnings the bar is high. We break down Vyjuvek, the pipeline, and whether risk-reward still works.

DeepValue Research TeamRead article →

January 29, 2026

Arcellx (ACLX) Deep Research Report: High-Expectation Biotech Where Patience May Pay Off

Arcellx is priced like a near‑term CAR‑T winner. We break down the data, risks, and valuation to see if waiting offers better upside.

DeepValue Research TeamRead article →

January 28, 2026

Axsome Therapeutics (AXSM) Deep Research Report: Elevated Expectations, Tight Margins of Safety, and What Could Reset the Risk‑Reward

Axsome’s stock has surged on big CNS growth hopes. We break down what’s priced in, key 2026 catalysts, and where risk‑reward turns attractive.

DeepValue Research TeamRead article →

January 28, 2026

Vertex Pharmaceuticals (VRTX) Deep Research Report: Stretched Valuation, Launch Execution Risks, and What Needs to Change by 2027

Our deep dive into Vertex weighs CF strength against slow Casgevy and Journavx monetization, rising costs, and what that means for VRTX stock holders.

DeepValue Research TeamRead article →

January 28, 2026

Exelixis (EXEL) Deep Research Report: Waiting for a Better Entry in 2026 – What Needs to Go Right (and Wrong)

Deep dive on Exelixis valuation, Cabometyx durability, zanzalintinib upside, and 2026–2028 risk factors to see if patience beats chasing the rally.

DeepValue Research TeamRead article →

January 27, 2026

Veritone (VERI) Deep Research Report: High-Beta AI Exposure or Execution Risk in 2026?

Veritone’s AI pivot is driving fast software growth but thin safety. See what must go right by 2026 before treating VERI as a long-term winner.

DeepValue Research TeamRead article →

January 27, 2026

Global‑E Online Ltd. (GLBE) Deep Research Report: High-Growth Story vs. Tariff Risk in 2026–2027

Deep dive on Global‑E’s growth, Shopify partnership, tariff risk, and valuation. See whether GLBE looks like a wait, buy, or trim for 2026.

DeepValue Research TeamRead article →

January 27, 2026

Kulicke & Soffa Industries (KLIC) Deep Research Report: Advanced Packaging Upside vs. Valuation Risk in 2026–2027

Kulicke & Soffa’s AI and HBM packaging story is heating up, but is the stock already pricing in success? A deep look at risk, reward, and timing.

DeepValue Research TeamRead article →

January 26, 2026

Digital Turbine (APPS) Deep Research Report: Turnaround Hopes vs. Balance-Sheet Risk in 2026

Digital Turbine shares have surged, but leverage is high and execution risk is real. See if the current price justifies the turnaround story in 2026.

DeepValue Research TeamRead article →

January 26, 2026

Klaviyo (KVYO) Deep Research Report: 35% Upside or Value Trap at 5.5x Sales in 2026?

Klaviyo stock is down 38% yet still growing ~30% with strong cash flow. We break down upside, risks, Shopify dependence, and AI-fueled catalysts.

DeepValue Research TeamRead article →

January 26, 2026

ReposiTrak (TRAK) Deep Research Report: Traceability Tailwinds, Regulatory Delays, and What 2026 Investors Should Watch

Deep dive on ReposiTrak’s growth, margins, FSMA 204 delay, and valuation after a 50% selloff. Is this micro-cap SaaS finally at a buyable price?

DeepValue Research TeamRead article →

January 25, 2026

Hycroft Mining Holding Corp (HYMC) Deep Research Report: High-Grade Silver Hopes vs. Technical Risk in 2026

Deep dive on Hycroft Mining’s high-grade Nevada silver story, Q1 2026 catalysts, balance sheet risk, and whether the current micro-cap price misfires.

DeepValue Research TeamRead article →

January 25, 2026

AngloGold Ashanti (AU) Deep Research Report: Overvalued Gold Winner or Smart Hold Into the Next Cycle?

AngloGold Ashanti has surged 280% on record gold and cash flow. We break down valuation, risks, dividend durability, and 2026 scenarios for AU stock.

DeepValue Research TeamRead article →

January 23, 2026

Alaska Air Group (ALK) Deep Research Report: Overvalued vs. Execution Risk in a High-Stakes 2027 Earnings Ramp

Alaska Air trades like a fast-growing winner, but margins, outages and Hawaii risks tell a tougher story. Here’s how the risk‑reward really stacks up.

DeepValue Research TeamRead article →

January 23, 2026

Freshpet (FRPT) Deep Research Report: Wait for a Better Margin of Safety or Clearer Growth Proof?

Freshpet stock has rebounded from a deep selloff, but competition and rich multiples leave a thin margin of safety. See if the risk‑reward still works.

DeepValue Research TeamRead article →

January 22, 2026

Lifetime Brands (LCUT) Deep Research Report: Tariffs, Leverage, and 2027 Debt – Is Risk Now Outweighing Reward?

Deep dive on Lifetime Brands’ tariffs, leverage, and covenant risk at today’s price. See whether the risk/reward justifies holding or trimming the stock.

DeepValue Research TeamRead article →

January 22, 2026

VAALCO Energy (EGY) Deep Research Report: Undervalued Yield Play Or Execution Trap Going Into 2026?

Deep dive on VAALCO Energy’s valuation, dividend durability and 2026 growth drivers, including Gabon Phase 3 and Baobab FPSO restart risks.

DeepValue Research TeamRead article →

January 21, 2026

Kewaunee Scientific Corporation (KEQU) Deep Research Report: Growth With Jittery Margins – Is the Risk/Reward Finally Attractive?

Kewaunee Scientific’s growth is surging while margins wobble. We break down backlog, Nu Aire integration, leverage, and valuation to see if upside dominates.

DeepValue Research TeamRead article →

January 21, 2026

SoFi Technologies (SOFI) Deep Research Report: Dilution, Growth, and Risk: What 2026 Investors Need to Weigh

SoFi stock bakes in high growth and profitability—but also dilution and credit risk. We break down valuation, scenarios, and what to watch in 2026.

DeepValue Research TeamRead article →

January 20, 2026

WM Technology (MAPS) Deep Research Report: Cheap Cannabis Tech or Value Trap in 2026?

WM Technology looks cheap on cash and EBITDA, but shrinking ARPC and pressured cannabis markets cloud its 2026 upside. Here’s what investors should watch.

DeepValue Research TeamRead article →

January 20, 2026

Cricut (CRCT) Deep Research Report: Undervalued Platform Cash Machine Or Value Trap in 2026?

Deep dive on Cricut’s 2026 outlook: tariffs, engagement, margins, and dividend risk—why this cash-rich craft platform may be mispriced by the market.

DeepValue Research TeamRead article →

January 19, 2026

Jaguar Health (JAGX) Deep Research Report: Distressed Biotech Option or Value Trap for 2026–2028?

Deep dive on Jaguar Health’s distressed balance sheet, royalty cliff, and orphan-drug pipeline to see whether the stock is a speculative buy or a value trap.

DeepValue Research TeamRead article →

January 19, 2026

Northfield Bancorp, Inc. (NFBK) Deep Research Report: Priced for a Slow Grind Higher or Still Discounting Too Much Risk?

Deep dive on Northfield Bancorp’s dividend, CRE risk, valuation, and 2026 outlook to see if today’s discount to book offers enough margin of safety.

DeepValue Research TeamRead article →

January 18, 2026

ON Semiconductor (onsemi) (ON) Deep Research Report: Overvalued vs. Opportunity – What 2026 Investors Should Watch

ON Semiconductor sits at a cyclical trough with rich multiples, big SiC and AI bets, and a $6B buyback. Here’s what must improve before we’d buy.

DeepValue Research TeamRead article →

January 18, 2026

NXP Semiconductors (NXPI) Deep Research Report: 2026 Risk‑Reward Looks Balanced Until the Next Pullback

NXP Semiconductors is priced for a clean auto and industrial recovery. We break down 2026 EPS expectations, SDV/AI upside, and where value investors may want to wait.

DeepValue Research TeamRead article →

January 16, 2026

Rocket Companies (RKT) Deep Research Report: Overvalued vs. Opportunity Heading Into 2027?

Our deep-dive breaks down the bull and bear cases, valuation risks, and key 2026–27 milestones investors must watch before making a move.

DeepValue Research TeamRead article →

January 16, 2026

Chord Energy (CHRD) Deep Research Report: High Cash Returns, Long Laterals, and a Market That Still Doesn’t Believe

Chord Energy trades at deep value multiples despite high free cash flow, low leverage, and aggressive capital returns. Is the market too pessimistic?

DeepValue Research TeamRead article →

January 15, 2026

Cybin Inc. (Helus Pharma) (HELP) Deep Research Report: Overvalued vs. Opportunity in Psychedelic Biotech for 2026–2027

Deep dive on Cybin/Helus (HELP): CYB003, CYB004, cash burn, dilution risk, and what the 2026 data calendar means for risk‑reward at today’s price.

DeepValue Research TeamRead article →

January 15, 2026

Enveric Biosciences (ENVB) Deep Research Report: High-Risk Micro-Cap or Optionality Play for 2026?

Deep dive on Enveric Biosciences: cash runway, Nasdaq risk, EB-003 pipeline, dilution math, and what has to go right before 2026 for equity to work.

DeepValue Research TeamRead article →

January 14, 2026

GH Research PLC (GHRS) Deep Research Report: High-Risk Upside or Fully Priced Psychedelic Bet in 2026?

GH Research is racing toward Phase 3 with a cash-rich balance sheet and hyped TRD data. We break down if the current stock price still offers upside.

DeepValue Research TeamRead article →

January 14, 2026

Mind Medicine (MindMed) Inc. (MNMD) Deep Research Report: High-Hype Psychedelic Bet or Smart Trim Before 2026 Data?

MindMed’s MM120 could reshape anxiety treatment, but the stock already prices in success. We break down 2026 catalysts, dilution risk, and valuation.

DeepValue Research TeamRead article →

January 13, 2026

Compass Pathways plc (CMPS) Deep Research Report: Binary Psychedelic Bet or Prudent Patience for 2026–2027?

Compass Pathways has positive Phase 3 data, big upside talk, and high risk. See what 2026–2027 catalysts mean for CMPS stock and where value investors should wait.

DeepValue Research TeamRead article →

January 13, 2026

High Tide Inc. (HITI) Deep Research Report: Discount-Club Moat, German Expansion, And What 2026 Investors Should Watch

High Tide’s discount-club model is gaining share and cash flow, but leverage and German regulation add risk. See if the risk/reward still skews bullish.

DeepValue Research TeamRead article →

January 12, 2026

Tempus AI, Inc. (TEM) Deep Research Report: Lofty Growth Expectations Meet Execution Risk in 2026

Tempus AI stock bakes in aggressive growth and margin gains. We break down the upside, downside, and what 2026 investors should watch now.

DeepValue Research TeamRead article →

January 12, 2026

Kaspi.kz (KSPI) Deep Research Report: Undervalued Super-App Facing Turkish Growing Pains in 2026

Kaspi.kz trades at a single-digit P/E despite 40%+ ROE. We break down Kazakhstan strength, Turkey risk, new taxes, and what that means for 2026 returns.

DeepValue Research TeamRead article →

January 11, 2026

DocuSign (DOCU) Deep Research Report: Can A High-Margin “Utility” Turn Into A Double-Digit Grower Again by 2027?

Deep dive on DocuSign’s 2026–2027 outlook: IAM adoption, ARR guidance, risks from Adobe/Microsoft, and whether current valuation still offers upside.

DeepValue Research TeamRead article →

January 11, 2026

Danaher Corporation (DHR) Deep Research Report: Priced for a 2026 Rebound – Or Time to Lock In Gains?

Danaher trades at a rich multiple on a tools rebound story. We break down growth, margins, risks and valuation to see if DHR is a buy or a trim.

DeepValue Research TeamRead article →

January 9, 2026

Constellation Brands (STZ) Deep Research Report: Margin Pressured or Opportunity in 2026? What Long-Term Investors Should Watch

Constellation Brands’ stock is down sharply, but beer margins stay rich. We break down volumes, tariffs, capex, and what must go right for upside.

DeepValue Research TeamRead article →

January 9, 2026

Sprouts Farmers Market (SFM) Deep Research Report: Oversold Opportunity or Value Trap After the 40% Drawdown?

Sprouts Farmers Market stock is down over 40%. We break down comps, margins, litigation risk and valuation to see if the selloff is a buying chance.

DeepValue Research TeamRead article →

January 8, 2026

SBC Medical Group Holdings Inc. (SBC) Deep Research Report: Restructuring Pop or Durable Cash Machine by 2027?

SBC Medical looks cheap and cash-rich, but earnings quality, related-party risk, and cash flow make this a stock where patience may beat urgency.

DeepValue Research TeamRead article →

January 8, 2026

China Automotive Systems (CAAS) Deep Research Report: Deep Value, High Risk – Can This Auto Supplier Reward Patient Investors by 2027?

Deep dive on China Automotive Systems: valuation, growth drivers, risks, and scenarios for CAAS stock. Is this underfollowed auto supplier a value trap or opportunity?

DeepValue Research TeamRead article →

January 7, 2026

Greenland Technologies Holding Corp. (GTEC) Deep Research Report: Deep Value or Value Trap for 2026 Micro-Cap Investors?

GTEC trades near liquidation-style multiples despite positive cash flow and 30% gross margins. We break down the real risks, upside, and what to watch.

DeepValue Research TeamRead article →

January 7, 2026

Transportadora de Gas del Sur S.A. (TGS) Deep Research Report: Waiting for Proof or a Better Price in a High-Risk, High-Reward Market

Deep dive on TGS ADRs: valuation, tariffs, Vaca Muerta growth and Argentina risk. Why we rate it a wait and what must go right before buying.

DeepValue Research TeamRead article →

January 6, 2026

Tilray Brands (TLRY) Deep Research Report: Crowded Policy Trade Or Patient Value Play by 2028?

Tilray trades below book with reset assets and crowded cannabis hype. We break down impairments, dilution, and what must improve before it's a buy.

DeepValue Research TeamRead article →

January 6, 2026

POET Technologies Inc. (POET) Deep Research Report: Speculative AI Photonics Play With More Hype Than Proof?

POET trades near a $1B valuation on minimal revenue and heavy losses. We break down the AI optics story, dilution risk, and what must go right.

DeepValue Research TeamRead article →

January 5, 2026

Okta, Inc. (OKTA) Deep Research Report: Overvalued vs. Opportunity in Identity-First Security?

Deep dive on Okta’s profitability pivot, competitive risks, security overhang, and valuation to see whether the stock still offers attractive long-term upside.

DeepValue Research TeamRead article →

January 5, 2026

Cloudflare (NET) Deep Research Report: Priced for Perfection or Just Getting Started?

Cloudflare is growing fast with rising free cash flow—but is the stock’s lofty valuation justified, or are investors underwriting a perfection story?

DeepValue Research TeamRead article →

January 4, 2026

Halliburton (HAL) Deep Research Report: Cyclical Upside, Cash Returns, and What Could Break the Thesis

Halliburton trades below our intrinsic value estimate but faces a clear cyclical downshift. We break down risks, cash flows, and upside for patient investors.

DeepValue Research TeamRead article →

January 4, 2026

TechnipFMC (FTI) Deep Research Report: Quality Cyclical or Fully Priced Risk Play for Offshore Investors?

Deep dive on TechnipFMC’s subsea turnaround, backlog strength, and valuation risk. Is this quality cyclical still attractive after a 63% run‑up?

DeepValue Research TeamRead article →

January 2, 2026

Moody's Corporation (MCO) Deep Research Report: Richly Priced Oligopoly or Risky Bet on Perpetual Growth?

Moody’s combines an elite ratings oligopoly with fast-growing analytics, but its lofty valuation leaves little margin of safety for value investors.

DeepValue Research TeamRead article →

January 2, 2026

Republic Services (RSG) Deep Research Report: High-Quality Cash Flows, Thin Margin of Safety for 2026 Buyers

Republic Services offers resilient cash flows and ESG tailwinds, but rich valuation and environmental risks leave limited margin of safety for new investors.

DeepValue Research TeamRead article →

January 1, 2026

UiPath (PATH) Deep Research Report: Premium Valuation, Slowing ARR – Is the Risk‑Reward Still Attractive?

UiPath pairs high margins and cash with slowing ARR and rich valuation. We break down if the automation leader’s stock still offers upside.

DeepValue Research TeamRead article →

January 1, 2026

Concentrix (CNXC) Deep Research Report: Deep Value, High Leverage – Is the Risk/Reward Worth It in 2026?

Concentrix trades at deep-value multiples with strong FCF but elevated leverage and AI risk. We break down whether the risk/reward now favors patient investors.

DeepValue Research TeamRead article →

December 31, 2025

Oceaneering International (OII) Deep Research Report: Cyclical Upside or Value Trap at Today’s Premium Valuation?

Deep dive on Oceaneering’s earnings momentum, backlog strength, free cash flow volatility, and valuation risk for value-focused investors.

DeepValue Research TeamRead article →

December 31, 2025

Baker Hughes (BKR) Deep Research Report: Overvalued vs. Opportunity: What Investors Should Watch Next

Baker Hughes blends LNG growth and solid cash flow with cyclical risk and rich valuation. See if the risk/reward justifies trimming or holding.

DeepValue Research TeamRead article →

December 30, 2025

Bristow Group (VTOL) Deep Research Report: Cyclical Upside or Value Trap for 2026-Oriented Investors?

Deep dive on Bristow Group’s improving earnings, offshore cycle leverage, SAR contracts, and balance sheet risk to see if VTOL offers real value.

DeepValue Research TeamRead article →

December 30, 2025

Helix Energy Solutions Group (HLX) Deep Research Report: Deep Cyclical Upside or Value Trap at 0.6x Book?

Helix trades at a steep discount to book and DCF while delivering its best free cash flow in decades. We unpack the upside, risks, and key 2025–26 watchpoints.

DeepValue Research TeamRead article →

December 29, 2025

Constellation Energy (CEG) Deep Research Report: Bull vs. Bear Case for 2026 Investors Weighing Nuclear, AI and Policy Risk

Constellation’s nuclear scale, AI power demand and Calpine deal create upside—but rich valuation and volatile cash flows limit margin of safety.

DeepValue Research TeamRead article →

December 29, 2025

Vistra Corp. (VST) Deep Research Report: Priced for Perfection in 2026 – Or Is It Time to Trim?

Deep dive on Vistra (VST): cash flow strength, nuclear/IRA tailwinds, policy and leverage risks, and why our team sees limited upside at today’s price.

DeepValue Research TeamRead article →

December 25, 2025

Range Resources (RRC) Deep Research Report: Overvalued or a Gas-Levered Opportunity for 2026 Investors?

Our deep dive into Range Resources (RRC) shows a quality, low-cost gas producer trading at rich multiples with limited margin of safety at current prices.

DeepValue Research TeamRead article →

December 24, 2025

Viper Energy (VNOM) Deep Research Report: A Smart Income Play or a Governance Risk in 2026?

Deep dive on Viper Energy (VNOM): Permian royalty model, cash flows, leverage, Sitio deal, and whether the stock looks attractive for long-term income investors.

DeepValue Research TeamRead article →

December 23, 2025

Diamondback Energy (FANG) Deep Research Report: A Buy for Permian Exposure and Free Cash Flow in 2026?

Deep dive on Diamondback Energy’s Permian scale, free cash flow, leverage, and 2026 impairment risk to see if FANG stock is attractive now.

DeepValue Research TeamRead article →

December 22, 2025

Texas Pacific Land Corporation (TPL) Deep Research Report: Too Expensive After the AI Boom?

Texas Pacific Land combines elite Permian royalties with AI and water upside—but a rich valuation leaves little margin of safety for value investors.

DeepValue Research TeamRead article →

December 21, 2025

Power Solutions International (PSIX) Deep Research Report: Overvalued After a 258% Run?

Power Solutions International’s turnaround is real, but is PSIX stock priced for perfection? We break down growth, risks, valuation, and 2025–2027 outlook.

DeepValue Research TeamRead article →

December 20, 2025

NRG Energy (NRG) Deep Research Report: Priced For Perfection Or Still Worth Holding In 2026?

NRG is riding the data-center power boom, but high leverage and rich valuation limit margin of safety. We break down risks, cash flows, and what investors should watch.

DeepValue Research TeamRead article →

December 19, 2025

EQT Corporation (EQT) Deep Research Report: Worth the Premium After Its Midstream Merger and LNG Pivot?

Deep dive on EQT stock: integrated gas plus midstream, LNG upside, debt reduction, and why today’s premium valuation leaves a slim margin of safety.

DeepValue Research TeamRead article →

December 18, 2025

Chevron Corporation (CVX) Deep Research Report: Still Worth Holding at a Premium in 2026?

Chevron offers quality assets, strong cash flow, and a rising dividend—but trades ~32% above DCF. We break down whether CVX is still worth holding.

DeepValue Research TeamRead article →

December 17, 2025

Textron Inc. (TXT) Deep Research Report: Is it Priced for Perfection in 2026 – Or Is It Time to Trim?

Textron mixes strong aviation and defense assets with solid cash flow—but TXT stock trades rich to FCF. We break down risks, catalysts, and valuation.

DeepValue Research TeamRead article →

December 16, 2025

International Seaways (INSW) Research Report: A Cyclical Value Opportunity For 2025–2027 Investors?

International Seaways (INSW) offers leveraged tanker exposure, strong cash returns, and a de-risked balance sheet. Is the stock undervalued today?

DeepValue Research TeamRead article →

December 15, 2025

Antero Midstream Corporation (AM) Stock Analysis: Still a Buy After Its 20% Run, or Just an Income Hold for 2026?

Deep dive on Antero Midstream (AM): dividend safety, cash flows, risks, valuation, and what investors should watch before buying after a 20% rally.

DeepValue Research TeamRead article →

December 14, 2025

Antero Resources (AR) Stock Analysis: Is Antero Resources Worth the Risk for Natural Gas Bulls in 2025–2026?

Deep dive on Antero Resources stock: gas/NGL leverage, HG Energy deal, deleveraging targets, valuation, risks, and what investors should watch next.

DeepValue Research TeamRead article →

December 13, 2025

Aemetis, Inc. (AMTX) Stock Analysis: Is Aemetis a Deep Value Play or a Value Trap in 2025?

Deep dive on Aemetis (AMTX): balance sheet stress, going‑concern risk, RNG and SAF upside, and what today’s valuation really implies for investors.

DeepValue Research TeamRead article →

December 12, 2025

NextDecade Corporation (NEXT) Stock Analysis: Is NEXT a Binary Bet or a 10-Year LNG Winner?

Deep research on NextDecade (NEXT): Rio Grande LNG status, FERC/DOE risk, leverage, and what needs to go right for long-term investors.

DeepValue Research TeamRead article →

December 11, 2025

Ameren Corporation (AEE) Stock Analysis: Is Ameren A Fairly Valued Utility Or A Buy-On-Dip Opportunity For 2025?

Deep dive on Ameren (AEE): regulated monopoly, 10% rate-base growth, heavy capex, equity dilution, and regulatory/ESG risks for long-term investors.

DeepValue Research TeamRead article →

December 10, 2025

SM Energy (SM) Stock Analysis: Deep Dive on Valuation, Cash Flow, and the Civitas Merger

SM Energy (SM) trades at low multiples despite strong cash flow and reserves. We break down valuation, risks, Uinta, and the pending Civitas merger.

DeepValue Research TeamRead article →

December 9, 2025

Crescent Energy (CRGY) Stock Analysis: Leverage, Reserves, and Roll-Up Risk

Deep research of Crescent Energy (CRGY) stock: reserves vs. leverage, KKR governance, Vital deal risk, and FCF for value-focused investors.

DeepValue Research TeamRead article →

December 8, 2025

ExxonMobil (XOM) Stock Analysis: Cash Flows, Capex, and Energy Transition Risk

Our deep research on ExxonMobil (XOM) stock reviews cash flow strength, capex plans, energy transition risks, and upside potential for long-term investors.

DeepValue Research TeamRead article →

December 7, 2025

Occidental Petroleum (OXY) Stock Analysis: Deleveraging, Permian Growth & CCUS Optionality

Our deep research on Occidental Petroleum (OXY) reviews Permian growth, deleveraging, the OxyChem sale, CCUS/DAC upside and key risks for long-term investors.

DeepValue Research TeamRead article →

December 6, 2025

Matador Resources (MTDR) Stock Analysis: Delaware Basin Growth, Midstream Moat & Valuation Deep Dive

Our MTDR stock deep research reviews Delaware Basin growth, midstream assets, free cash flow, risks and valuation to see if Matador is a buy.

DeepValue Research TeamRead article →

December 5, 2025

Vital Energy (VTLE) Stock Analysis: Event-Driven Deep Research on a Leveraged Permian Producer

Vital Energy (VTLE) is being acquired by Crescent Energy. We unpack its leverage, cash flows, Permian assets, and deal-driven setup for investors.

DeepValue Research TeamRead article →

December 4, 2025

Canadian Natural Resources Stock Analysis (CNQ): Deep Dive on Valuation, FCF, and Policy Risk

In-depth CNQ stock research: valuation, free cash flow strength, oil sands moat, and climate-policy risks for long-term investors.

DeepValue Research TeamRead article →

December 3, 2025

Enterprise Products Partners (EPD) Stock Analysis: Distribution Strength, Leverage, and Long-Term Midstream Moat

Enterprise Products Partners (EPD) stock deep research on distribution safety, leverage, growth projects, and risks for long-term income investors in 2025.

DeepValue Research TeamRead article →

December 2, 2025

Williams Companies (WMB) Stock Analysis: Lofty Valuation vs. Cash Flow Reality

Deep research on Williams (WMB) stock: valuation, leverage, cash flows, and risk factors for income and value investors assessing this midstream leader.

DeepValue Research TeamRead article →

December 1, 2025

BigBear.ai (BBAI) Stock Analysis: Why This AI Defense Play Looks Overpriced After a Huge Run

Deep research on BigBear.ai (BBAI) stock, its AI defense story, revenue outlook, capital structure, and risks after a ~199% 12‑month rally.

DeepValue Research TeamRead article →

November 30, 2025

Copart (CPRT) Stock Analysis: Margin Strength, FCF Growth, and a 2025 Value Opportunity

Copart (CPRT) stock deep research: high margins, strong free cash flow, net cash balance sheet, and a 26% DCF discount. Is this pullback a buying chance?

DeepValue Research TeamRead article →

November 29, 2025

CleanSpark (CLSK) Stock Analysis: Bitcoin Mining Leverage with AI/HPC Optionality

Deep dive on CleanSpark (CLSK) stock: Bitcoin‑levered miner with modern fleet, light leverage, negative FCF, and AI/HPC upside. Is the risk/reward worth it?

DeepValue Research TeamRead article →

November 28, 2025

TeraWulf (WULF) Stock Analysis: AI, Bitcoin, and a Stretched Valuation?

Detailed TeraWulf (WULF) stock deep research covering AI/HPC strategy, bitcoin exposure, leverage, dilution risk, and what investors should watch next.

DeepValue Research TeamRead article →

November 27, 2025

Arq Inc. (ARQ) Stock Analysis: Deep Research on a High-Risk Environmental Play

Arq (ARQ) looks optically cheap, but GAC ramp issues, thin liquidity, and execution risk dominate the story. See if the risk/reward fits your strategy.

DeepValue Research TeamRead article →

November 26, 2025

Joby Aviation (JOBY) Stock Analysis: High-Risk eVTOL Leader With Long-Dated Upside

Deep research on Joby Aviation (JOBY) stock: cash runway, FAA certification timing, revenue trends, and risk/reward for eVTOL investors.

DeepValue Research TeamRead article →

November 25, 2025

Harrow Health (HROW) Stock Analysis: High-Growth Ophthalmology Play With Stretched Balance Sheet

Deep research on Harrow Health (HROW) stock: growth, margins, leverage, and regulatory risk in its ophthalmic portfolio. Is the risk/reward still attractive?

DeepValue Research TeamRead article →